Diana Povoas

Dr. Diana Povoas


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in The Lancet Microbe
Verified
Journal Article
Open access
JCJameson Crandell
Jameson Crandell
VMValter Silva Monteiro
Valter Silva Monteiro
LPLauren Pischel
Lauren Pischel
ZFZhenhao Fang
Zhenhao Fang
LCLuciana Conde
Luciana Conde
CLCarolina Lucas
Carolina Lucas
Cross-reactive immune memory responses to orthopoxviruses in humans remain poorly characterised despite their relevance for vaccine design and outbreak control. We aimed to assess the magnitude, specificity, and durability of cross-reactive immune responses elicited by smallpox vaccines and mpox virus infection. We did a multicohort observational study involving participants from the USA, Brazil, and Portugal across four groups: Dryvax (first-generation smallpox vaccine) recipients vaccinated 40-80 years ago, JYNNEOS (third-generation smallpox vaccine) recipients vaccinated within the past year, a cohort receiving both vaccines, and patients infected with clade IIb mpox. Samples were analysed for systemic and mucosal humoral responses, neutralising antibody titres, viral antigen structural analysis, and T-cell cross-reactivity to vaccina virus, cowpox virus, and mpox virus. Statistical analyses included correlation assessments and comparisons across cohorts to determine the magnitude, longevity, and breadth of immune responses. Between July 7, 2022, and Aug 3, 2023, 262 participants were recruited, resulting in analysis of 378 samples. Both first-generation and third-generation smallpox vaccines elicited vaccinia virus-reactive and mpox virus-reactive antibodies, with the strongest responses targeting the less conserved extracellular virion antigens B5 and A33. Despite high concentrations of anti-mpox virus antibodies in the plasma, cross-neutralisation activity correlated with viral antigenic distance. Higher neutralisation was observed for cowpox virus than for mpox virus, which has lower antigenic conservation with vaccina virus. Complement-mediated neutralisation enhanced mpox virus neutralisation, overcoming the limitations of antigenic distance. Dryvax recipients sustained vaccina virus neutralisation titres for over 80 years, whereas cross-reactive responses did not show this durability. JYNNEOS-induced responses waned within a year. T-cell cross-reactivity was long-lasting, detected up to 70 years after vaccination. Booster vaccinations augmented the magnitude, breadth, and longevity of cross-neutralising responses. Our findings highlight the potential combined role of antibody effector functions and T-cell memory in cross-protection against orthopoxviruses. Complement-mediated neutralisation enhances cross-protection, overcoming antigenic distance. These Fc-mediated functions, along with T-cell responses, contribute to effective and long-lasting immunity conferred by smallpox vaccines against other orthopoxviruses. Yale University and Stavros Niarchos Foundation Institute for Global Infectious Disease.

28 September 2022 in Medical Mycology Case Reports
Verified
Journal Article
Open access
JCJoão Pedro Bretes Menezes Caria
João Pedro Bretes Menezes Caria
ELEma Leal
Ema Leal
ADAndre Dias
Andre Dias
HPHelder Pinheiro
Helder Pinheiro
DPDiana Povoas
Diana Povoas
FMFernando Maltez
Fernando Maltez
Invasive fungal infections caused by Candida species are increasingly observed in immunosuppressed patients. Candida albicans is the more often identified species and neurocandidiasis is associated with high mortality rates. Diagnosis and treatment of these infections are frequently challenging.

28 November 2025 in Viruses
Verified
Journal Article
Open access
PDF file
RCRita Cordeiro
Rita Cordeiro
JCJoão Pedro Bretes Menezes Caria
João Pedro Bretes Menezes Caria
DSDaniel Sobral
Daniel Sobral
DPDiana Povoas
Diana Povoas
Monkeypox virus (MPXV) re-emerged in 2022 with a global outbreak that affected more than 100,000 individuals worldwide. People living with HIV (PLWH) accounted for a substantial proportion of cases, raising concerns about disease presentation, management, and outcomes in this population. Evidence indicates that PLWH with advanced or uncontrolled HIV infection experienced more severe mpox, with higher hospitalization rates, more complications, and longer disease courses. In contrast, individuals with well-controlled HIV generally had outcomes similar to those without HIV. Access to timely diagnosis, consistent antiretroviral therapy, and availability of tecovirimat were key factors influencing prognosis. Reports also suggest bidirectional interactions between mpox and HIV pathogenesis. Immune activation and APOBEC3-related viral evolution have been proposed; however, these mechanisms remain incompletely characterized and warrant further investigation. Moreover, disparities in healthcare access and stigma compound the vulnerability of PLWH, emphasizing the need for integrated approaches.

21 January 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
DPDiana Povoas
Diana Povoas
JDJocelyne Demengeot
Jocelyne Demengeot
FMFernando Maltez
Fernando Maltez
Occupationally acquired cases of the intracellular parasite Toxoplasma gondii have been reported, even though there is uncertainty on which infection prevention measures should be implemented in such event. We report a clinical case of laboratory-acquired toxoplasmosis and propose a protocol for post-exposure prophylaxis, given there are no formal guidelines. In this community case study, we describe the management and prevention protocol following an occupational laboratory exposure by a healthy 30-year-old Toxoplasma -seronegative female researcher who suffered an accidental needle puncture with a sample containing a genetically modified hypervirulent Toxoplasma gondii strain. Post-exposure prophylaxis (PEP) with trimethoprim-sulfamethoxazole was implemented for 4 weeks, during which seroconversion occurred, without any accompanying symptoms. Toxoplasma IgM and IgG positivity was observed 21 and 50 days after exposure, respectively, using a validated commercial electrochemiluminescence immunoassay (ECLIA, Roche). Follow-up was maintained for 1 year, during which the patient remained asymptomatic. This report highlights the importance of special care, surveillance and decision on the need for PEP upon occupational laboratory accidental exposure to Toxoplasma gondii . Since there are no guidelines on what the optimal PEP regimen should be, after a literature review, we propose a PEP occupational safety protocol to be implemented in laboratories that handle samples containing Toxoplasma gondii , either in clinical or research setting.

8 October 2021 in Portuguese Journal of Nephrology & Hypertension
Verified
Journal Article
Closed access
HUHospital de Curry Cabral Infectious Diseases Unit
Hospital de Curry Cabral Infectious Diseases Unit
DPDiana Povoas
Diana Povoas
Immunosuppressive drugs are the cornerstone of treatment of auto-immune inflammatory diseases (AIIDs) with renal involvement. How‑ ever, the most commonly used drugs in this setting can increase the risk of bacterial, fungal, and viral infection, and also impair immune response following vaccination. Recommendations and evidence on strategies for infection prevention in the setting of AIIDs treatment will be reviewed.